

Strategies to Overcome Endocrine Therapy Resistance in HR-Positive/ HER2-Negative Breast Cancer

Faculty Presentations:

Treatment adherence and persistence

Resource	Address
Chan AHY, et al. <i>Front Pharmacol.</i> 2020;11:572.	https://www.frontiersin.org/articles/10.3389/fphar.2020.00572/full
Denton E, Conron M. <i>J Multidiscip Healthc.</i> 2016;9:137-144.	https://www.dovepress.com/improving-outcomes-in-lung-cancer-the-value-of-the-multidisciplinary-h-peer-reviewed-fulltext-article-JMDH
Gast A, Mathes T. <i>Syst Rev.</i> 2019;8(1):112.	https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-019-1014-8
Greer JA, et al. <i>Oncologist.</i> 2016;21:354-376.	https://academic.oup.com/oncolo/article/21/3/354/6401333?login=false
Hanna K, Mayden K. <i>J Adv Pract Oncol.</i> 2021;12(suppl 2):13-20.	https://www.advancedpractitioner.com/cme-supplements/volume-12,-number-2-(mar-2021)/the-use-of-real-world-evidence-for-oral-chemotherapies-in-breast-cancer.aspx
Hernandez-Aya L, Ma CX. <i>Chin Clin Oncol.</i> 2016;5(3):42.	https://cco.amegroups.org/article/view/9845/11239
Jacobs JM, et al. <i>J Oncol Pract.</i> 2017;13:e474-e485.	https://ascopubs.org/doi/10.1200/JOP.2016.019729
Jazowski J. <i>Cancer.</i> 2020;126:3613-3616.	https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.32944
Kleinsinger F. <i>Perm J.</i> 2018;22:18-033.	https://www.thepermanentejournal.org/doi/10.7812/TPP/18-033
Lambourne T, et al. <i>J Cancer Educ.</i> 2019;34:1024-1030.	https://link.springer.com/article/10.1007/s13187-018-1406-9
Lasala R, Santoleri F. <i>Br J Clin Pharmacol.</i> 2022;88(5):1999-2018.	https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15147
Thomas SA, et al. <i>US Pharm.</i> 2019;44:HS-9-HS-12.	https://www.uspharmacist.com/article/challenges-to-oral-chemotherapy-adherence
Yang J, et al. <i>J Oncol Pract.</i> 2016;12:e800-e809.	https://ascopubs.org/doi/10.1200/JOP.2016.011742
Yang S, et al. <i>J Breast Cancer.</i> 2023;26(4):309-333.	https://ejbc.kr/DOIx.php?id=10.4048/jbc.2023.26.e22

CDK4/6 inhibitor clinical trial data

Resource	Address
Abemaciclib (Verzenio®) prescribing information (PI) 2023.	https://pi.lilly.com/us/verzenio-uspi.pdf
AlFakeeh A, Brezden-Masley C. <i>Curr Oncol.</i> 2018;25(suppl 1):S18-S27.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001756/

Bachelot T. <i>Ann Oncol.</i> 2021;32(4):574-575.	https://www.annalsofoncology.org/article/S0923-7534(21)00107-1/fulltext
Brufsky AM, Dickler MN. <i>Oncologist.</i> 2018;23:528-539.	https://academic.oup.com/oncolo/article/23/5/528/6439612?login=false
Chen WC. American Society of Clinical Oncology (ASCO) 2020; Abstract 360922.	https://meetings.asco.org/abstracts-presentations/206114
Cheng R, et al. <i>Cancer Epidemiol Biomarkers Prev.</i> 2012;21:800-809.	https://aacrjournals.org/cebp/article/21/5/800/69328/Hazard-of-Recurrence-among-Women-after-Primary
Corona SP, et al. <i>Drug Des Devel Ther.</i> 2018;12:321-330.	https://www.dovepress.com/abemaciclib-a-cdk46-inhibitor-for-the-treatment-of-hrher2-advanced-bre-peer-reviewed-fulltext-article-DDDT
Cristofanilli M, et al. <i>Clin Cancer Res.</i> 2022;28(16):3433-3442.	https://aacrjournals.org/clincancerres/article/28/16/3433/707399/Overall-Survival-with-Palbociclib-and-Fulvestrant
Cristofanilli M, et al. <i>Lancet Oncol.</i> 2016;17(4):425-439.	https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00613-0/fulltext
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). <i>Lancet.</i> 2015;386:1341-1352.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)61074-1/fulltext
Fasching P, et al. European Society for Medical Oncology (ESMO) Virtual Plenary 2023. <i>Ann Oncol.</i> 2023;34(10):951-953.	https://www.sciencedirect.com/science/article/pii/S0923753423008050
Finn RS, et al. <i>N Engl J Med.</i> 2016;375(20):1925-1936.	https://www.nejm.org/doi/10.1056/NEJMoa1607303
Finn RS. ASCO 2022; Abstract LBA1003.	https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.17_suppl.LBA1003
Goetz MP, et al. <i>J Clin Oncol.</i> 2017;35(32):3638-3646.	https://ascopubs.org/doi/10.1200/JCO.2017.75.6155
Goetz MP. ESMO 2022; Abstract LBA15.	https://oncologypro.esmo.org/meeting-resources/esmo-congress-2022/monarch-3-interim-overall-survival-os-results-of-abemaciclib-plus-a-nonsteroidal-aromatase-inhibitor-nsai-in-patients-pts-with-hr-her2-ad
Goodwin PJ, et al. <i>JAMA.</i> 2022;327(20):1963-1973.	https://jamanetwork.com/journals/jama/fullarticle/2792615
Hamilton EP, et al. ASCO 2023; Abstract 501.	https://meetings.asco.org/abstracts-presentations/218406
Harbeck N, et al. <i>Ann Oncol.</i> 2021;32(12):1571-1581.	https://www.annalsofoncology.org/article/S0923-7534(21)04494-X/fulltext
Harbeck N, et al. ESMO Breast 2023; Abstract 93MO. <i>Ann Oncol.</i> 2023;34(1 suppl 4):101219-101219.	https://oncologypro.esmo.org/meeting-resources/esmo-breast-cancer-2023/long-term-patient-reported-outcomes-from-monarche-abemaciclib-plus-endocrine-therapy-for-adjuvant-hr-her2-node-positive-high-risk-early-breast-cancer-ebc

Hortobagyi GN, et al. <i>N Engl J Med</i> . 2016;375(18):1738-1748.	https://www.nejm.org/doi/10.1056/NEJMoa1609709
Hortobagyi GN, et al. <i>N Engl J Med</i> . 2022;386(10):942-950.	https://www.nejm.org/doi/10.1056/NEJMoa2114663
Hurvitz SA, et al. <i>Clin Cancer Res</i> . 2020;26:566-580.	https://aacrjournals.org/clincancerres/article/26/3/566/83167/Potent-Cell-Cycle-Inhibition-and-Upregulation-of
Jerzak KJ, et al. <i>Curr Oncol</i> . 2023;30(6):5425-5447.	https://www.mdpi.com/1718-7729/30/6/411
Johnston SRD, et al. <i>J Clin Oncol</i> . 2020;38(34):3987-3998 including supplemental appendix.	https://ascopubs.org/doi/10.1200/JCO.20.02514
Johnston SRD, et al. <i>Lancet Oncol</i> . 2023;24(1):77-90.	https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00694-5/fulltext
Loibl S, et al. San Antonio Breast Cancer Symposium (SABCS) 2020; Abstract GS1-02.	https://www.sabcs.org/Portals/SABCS2016/2020%20SABCS/ALL%20ABSTRACTS%202-9.pdf?ver=2020-12-09-104626-337
Lu Y-S, et al. <i>Clin Cancer Res</i> . 2022;28(5):851-859.	https://aacrjournals.org/clincancerres/article/28/5/851/681697/Updated-Overall-Survival-of-Ribociclib-plus
Martin M, et al. <i>JAMA Oncol</i> . 2022;8(8):1190-1194 including supplemental appendix.	https://jamanetwork.com/journals/jamaoncology/fullarticle/2793128
Martin M, et al. <i>JAMA Oncol</i> . 2022;8(8):1190-1194.	https://jamanetwork.com/journals/jamaoncology/fullarticle/2793128
Mayer E. ESMO 2020; Abstract LBA12.	https://www.annalsofoncology.org/article/S0923-7534(20)42322-1/fulltext
Mayer EL, et al. <i>J Clin Oncol</i> . 2022;40(5):449-458.	https://ascopubs.org/doi/10.1200/JCO.21.01918
Mayer EL, et al. <i>Lancet Oncol</i> . 2021;22:212-222.	https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30642-2/fulltext
monarchE. NCT03155997.	https://clinicaltrials.gov/ct2/show/NCT03155997
NATALEE. NCT03701334.	https://clinicaltrials.gov/ct2/show/NCT03701334
Neven P. ESMO 2022; Abstract LBA4.	https://oncologypro.esmo.org/meeting-resources/esmo-breast-cancer-congress-2022/updated-overall-survival-os-results-from-the-first-line-1l-population-in-the-phase-iii-monaleesa-3-trial-of-postmenopausal-patients-pts-with
O'Shaughnessy JA, et al. SABCS 2020; Abstract GS1-01.	https://www.sabcs.org/Portals/SABCS2016/2020%20SABCS/ALL%20ABSTRACTS%202-9.pdf?ver=2020-12-09-104626-337
O'Shaughnessy J, et al. ESMO 2023; Abstract 274P.	https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal_2/presentation/list?q=abemaciclib
Otto T, Sicinski P. <i>Nat Rev Cancer</i> . 2017;17:93-115.	https://www.nature.com/articles/nrc.2016.138

Pagani O, et al. <i>J Clin Oncol</i> . 2020;38(12):1293-1303.	https://ascopubs.org/doi/10.1200/JCO.18.01967
Palbociclib (Ibrance®) PI 2019.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207103s008lbl.pdf
PALLAS. NCT02513394.	https://clinicaltrials.gov/ct2/show/NCT02513394
PENELOPE-B. NCT01864746.	https://clinicaltrials.gov/ct2/show/NCT01864746
Pfeiler G, et al. <i>J Clin Oncol</i> . 2023;41(33):5118-5130.	https://ascopubs.org/doi/10.1200/JCO.23.00126
Ribociclib (Kisqali®) PI 2022.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209092s013,209935s021lbl.pdf
Rugo HS, et al. <i>Ann Oncol</i> . 2022;33(6):616-627.	https://www.annalsofoncology.org/article/S0923-7534(22)00383-0/fulltext
Rugo HS, et al. <i>Breast Cancer Res Treat</i> . 2019;174(3):719-729.	https://link.springer.com/article/10.1007/s10549-018-05125-4
Slamon DJ, et al. <i>J Clin Oncol</i> . 2018;36(24):2465-2472.	https://ascopubs.org/doi/10.1200/JCO.2018.78.9909
Slamon DJ, et al. <i>Ann Oncol</i> . 2021;32(8):1015-1024.	https://www.annalsofoncology.org/article/S0923-7534(21)01553-2/fulltext
Slamon DJ, et al. ASCO 2023; Abstract LBA500.	https://meetings.asco.org/abstracts-presentations/218407
Slamon DJ, et al. <i>J Clin Oncol</i> . 2019;37(suppl 15); Abstract TPS597.	https://meetings.asco.org/abstracts-presentations/177724/poster
Slamon DJ, et al. <i>Ther Adv Med Oncol</i> . 2023;15:17588359231178125.	https://journals.sagepub.com/doi/10.1177/17588359231178125
Sledge GW, et al. <i>J Clin Oncol</i> . 2017;35(25):2875-2884.	https://ascopubs.org/doi/10.1200/JCO.2017.73.7585
Sledge GW, et al. <i>JAMA Oncol</i> . 2020;6(1):116-124.	https://jamanetwork.com/journals/jamaoncology/fullarticle/2752266
TRADE. NCT06001762.	https://clinicaltrials.gov/study/NCT06001762
Tripathy D, et al. <i>Clin Cancer Res</i> . 2017;23:3251-3262.	https://aacrjournals.org/clincancerres/article/23/13/3251/80177/Ribociclib-LEE011-Mechanism-of-Action-and-Clinical
Tripathy D, et al. <i>Lancet Oncol</i> . 2018;19(7):904-915.	https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30292-4/fulltext

Shared decision-making

Resource	Address
Agency for Healthcare Research and Quality (AHRQ). The SHARE Approach.	https://www.ahrq.gov/health-literacy/professional-training/shared-decision/index.html#:~:text=AHRQ%27s%20SHARE%20Approach%20is%20a,matters%20most%20to%20the%20patient.
AHRQ. Strategy 6I: Shared decision-making.	www.ahrq.gov/sites/default/files/wysiwyg/cahps/quality-improvement/improvement-guide/6-

	strategies-for-improving/communication/cahps-strategy-section-6-i.pdf
AHRQ. The SHARE Approach fact sheet.	www.ahrq.gov/sites/default/files/publications/files/share-approach_factsheet.pdf
Elwyn G, et al. <i>J Gen Intern Med</i> . 2012;27(10):1361-1367.	https://link.springer.com/article/10.1007/s11606-012-2077-6
Stacey D, et al. <i>Cochrane Database of Syst Rev</i> . 2017;4:CD001431.	https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001431.pub5/full

Script

Resource	Address
Abemaciclib (Verzenio®) PI 2023.	https://pi.lilly.com/us/verzenio-uspi.pdf
Chirgwin JH, Giobbie-Hurder A, Coates AS, et al. <i>J Clin Oncol</i> . 2016;34(21):2452-2459.	https://ascopubs.org/doi/10.1200/JCO.2015.63.8619
Chung C, Collins A, Cui N. <i>Am J Health-Syst Pharm</i> . 2011;68(18):1740-1747.	https://academic.oup.com/ajhp/article-abstract/68/18/1740/5129327?redirectedFrom=fulltext&login=false
Cristofanilli M, Turner NC, Bondarenko I, et al. <i>Lancet Oncol</i> . 2016;17(4):425-439.	https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00613-0/fulltext
Deutsch S, Koerner P, Miller RT, et al. <i>J Oncol Pharm Pract</i> . 2016;22(1):68-75.	https://journals.sagepub.com/doi/10.1177/1078155214547664
Finn RS, Crown JP, Lang I, et al. <i>Lancet Oncol</i> . 2015;16(1):25-35.	https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)71159-3/fulltext
Greer JA, Amoyal N, Nisotel L, et al. <i>The Oncologist</i> . 2016;21(3):354-376.	https://academic.oup.com/oncolo/article/21/3/354/6401333?login=false
Hortobagyi GN, Stemmer SM, Burris HA, et al. <i>Ann Oncol</i> . 2018;29(7):1541-1547.	https://www.annalsofoncology.org/article/S0923-7534(19)32105-2/fulltext
Johnston SRD, Harbeck N, Hegg R, et al. <i>J Clin Oncol</i> . 2020;38(34):3987-3998.	https://ascopubs.org/doi/10.1200/JCO.20.02514
Johnston SRD, Toi M, O'Shaughnessy J, et al. <i>Lancet Oncol</i> . 2023;24(1):77-90.	https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00694-5/fulltext
Lambourne T, Minard LV, Deal H, et al. <i>J Cancer Educ</i> . 2019;34(5):1024-1030.	https://link.springer.com/article/10.1007/s13187-018-1406-9
Leveque D, Delpeuch A, Gourieux B. <i>Anticancer Res</i> . 2014;34(4):1573-1578.	https://ar.iijournals.org/content/34/4/1573.long
Li E, Schleif R, Edelen B. <i>J Oncol Pract</i> . 2013;9(5):e248-254.	https://ascopubs.org/doi/10.1200/JOP.2012.000814
Loibl S, Marmé F, Martin M, et al. <i>J Clin Oncol</i> . 2021;39(14):1518-1530.	https://ascopubs.org/doi/10.1200/JCO.20.03639
Ma CS. <i>Integr Pharm Res Pract</i> . 2014;3:11-24.	https://www.dovepress.com/role-of-pharmacists-in-optimizing-the-use-of-anticancer-drugs-in-the-peer-reviewed-fulltext-article-IPRP
Mayer EL, Dueck AC, Martin M, et al. <i>Lancet Oncol</i> . 2021;22(2):212-222.	https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30642-2/fulltext

Palbociclib (Ibrance®) PI 2019.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207103s008lbl.pdf
Ribociclib (Kisqali®) PI 2022.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209092s013,209935s021lbl.pdf
Rugo HS, Huober J, García-Sáenz JA, et al. <i>The Oncologist</i> . 2021;26(1):e53-e65.	https://academic.oup.com/oncolo/article/26/1/e53/6445319?login=false
Slamon DJ, Stroyakovskiy D, Yardley DA, et al. <i>J Clin Oncol</i> . 2023;41(17_suppl):LBA500-LBA500.	https://meetings.asco.org/abstracts-presentations/218407
Sledge GW, Toi M, Neven P, et al. <i>J Clin Oncol</i> . 2017;35(25):2875-2884.	https://ascopubs.org/doi/10.1200/JCO.2017.73.7585
The SHARE Approach.	https://www.ahrq.gov/health-literacy/professional-training/shared-decision/index.html
Tuffaha HW, Abdelhadi O, Omar SA. <i>Int J Clin Pharm</i> . 2012;34(1):27-31.	https://link.springer.com/article/10.1007/s11096-011-9600-4
Turner NC, Ro J, André F, et al. <i>N Engl J Med</i> . 2015;373(3):209-219.	https://www.nejm.org/doi/10.1056/NEJMoa1505270
Wilkie DJ, Werley HH, Berry DL, et al. <i>West J Nurs Res</i> . 2010;32(1):23-46.	https://journals.sagepub.com/doi/10.1177/0193945909348009
Yang S, Park SW, Bae SJ, et al. <i>J Breast Cancer</i> . 2023;26(4):309-333.	https://ejbc.kr/DOIx.php?id=10.4048/jbc.2023.26.e22

All URLs accessed December 4, 2023.